Rapid oral desensitization protocol to abiraterone acetate
Abiraterone acetate (AA) is a potent selective inhibitor of cytochrome P450 (CYP) 17, a key enzyme involved in testosterone synthesis. Due to this inhibition, the production of androgens by endocrine tissues decreases. Therefore, this oral hormone therapy is used in castration-resistant prostate cancer combined with prednisone/prednisolone, with a significant increase in overall survival. Common side effects of AA include hypertension, hypokalaemia, peripheral oedema and urinary tract infections.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Miriam Verdu, Virginia Torres-Degayon, Mohamed Hassan-Bennis Tags: Letter Source Type: research
More News: Abiraterone Acetate | Allergy | Allergy & Immunology | Asthma | Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | Hypertension | Oral Cancer | Prednisolone | Prednisone | Prostate Cancer | Urinary Tract Infections